Cargando…

The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers

Therapies for hormone-independent prostate and breast cancer are limited, with the effectiveness of the taxanes compromised by toxicity, lack of oral bioavailability and drug resistance. This study aims to identify and characterise new microtubule disruptors, which may have improved efficacy relativ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Newman, S P, Foster, P A, Ho, Y T, Day, J M, Raobaikady, B, Kasprzyk, P G, Leese, M P, Potter, B V L, Reed, M J, Purohit, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360283/ https://www.ncbi.nlm.nih.gov/pubmed/18026194 http://dx.doi.org/10.1038/sj.bjc.6604100

Ejemplares similares

Class III β-tubulin expression and in vitro resistance to microtubule targeting agents
por: Stengel, C, et al.
Publicado: (2010)

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol
por: Chander, S K, et al.
Publicado: (2007)

BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure
por: Day, J M, et al.
Publicado: (2009)

2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer
por: Tagg, S L C, et al.
Publicado: (2008)

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer
por: Stengel, C, et al.
Publicado: (2014)

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011)

Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol
por: Shen, Yu-chi, et al.
Publicado: (2015)

The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine
por: Bhoopathi, P, et al.
Publicado: (2010)

PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells
por: Maginn, E N, et al.
Publicado: (2011)

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy
por: Tazzari, M, et al.
Publicado: (2014)

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models
por: El-Emir, E, et al.
Publicado: (2007)

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo
por: Yao, K, et al.
Publicado: (2005)

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
por: Fürstenberger, G, et al.
Publicado: (2006)

Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane
por: Maloney, S L, et al.
Publicado: (2009)

Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors
por: Leese, Mathew P., et al.
Publicado: (2011)

Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead
por: Mangoni, M, et al.
Publicado: (2012)

β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma
por: Pasquier, E, et al.
Publicado: (2013)

Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents
por: Ireson, C R, et al.
Publicado: (2004)

Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer
por: Rosa, R, et al.
Publicado: (2013)

The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008)

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo
por: Akashi, Y, et al.
Publicado: (2007)

Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo
por: Hristodorov, D, et al.
Publicado: (2013)

N-(4-iodophenyl)-N′-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice
por: Borel, M, et al.
Publicado: (2007)

Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells
por: Carbajo-Pescador, S, et al.
Publicado: (2013)

Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice
por: Edrei, Y, et al.
Publicado: (2012)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut
por: Bach, S P, et al.
Publicado: (2006)

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model
por: Reed, M D, et al.
Publicado: (2013)

Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines
por: Barabutis, N, et al.
Publicado: (2008)

The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy
por: Miao, L, et al.
Publicado: (2014)

TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy
por: Lee, S Y, et al.
Publicado: (2010)

hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours
por: Nutt, J E, et al.
Publicado: (2007)

Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis
por: Schulz, P, et al.
Publicado: (2008)

Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells
por: Lucia, M B, et al.
Publicado: (2011)

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
por: Schayowitz, A, et al.
Publicado: (2010)

A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate
por: Falasca, M, et al.
Publicado: (2010)

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
por: Nutley, B P, et al.
Publicado: (2005)

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel
por: Uzoh, C C, et al.
Publicado: (2011)

Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
por: Reeder, A, et al.
Publicado: (2015)

Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development
por: Camidge, D R, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_aiilrnhcmfencgmk5rbeq14v1e